Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab

Uysal M., Bozcuk H., Göksu S. S., Tatlı A. M., Arslan D., Gunduz S., ...More

BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.4, pp.409-412, 2014 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 68 Issue: 4
  • Publication Date: 2014
  • Doi Number: 10.1016/j.biopha.2014.03.002
  • Journal Name: BIOMEDICINE & PHARMACOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.409-412
  • Keywords: Bevacizumab, Metastatic colorectal cancer, Prognostic and predictive factors, Proteinuria, PREOPERATIVE CARCINOEMBRYONIC ANTIGEN, FLUOROURACIL, LEUCOVORIN, HYPERTENSION, IRINOTECAN, OUTCOMES
  • Akdeniz University Affiliated: Yes

Abstract

Background: The beneficial effects of bevacizumab, a widely used agent in metastatic colorectal cancer (mCRC), on clinical survival have been proven. This study investigated the correlation of the clinical benefits and prognosis with proteinuria and other parameters.